Amikacin Dosing and Monitoring Guidelines

Adult Dosing (Normal Renal Function)

• For adult patients with normal renal function, give 15 mg/kg once daily (maximum 1.5 g per day) as an IV infusion over 30–60 min. 1
• The preferred daily regimen is 15 mg/kg once daily for 5–7 days per week during the initial treatment phase. 1
• Alternative divided‑dose regimens include 7.5 mg/kg every 12 h or 5 mg/kg every 8 h. 1

Intermittent (Thrice‑Weekly) Dosing

• After 2–4 months of therapy or after culture conversion, the dose can be reduced to 15–25 mg/kg three times per week, adjusted according to the efficacy of companion drugs. [1][2]

Age‑Related Adjustments

• Elderly patients (> 59 years): reduce to 10 mg/kg once daily (maximum 750 mg) to lower ototoxicity and nephrotoxicity risk. 2
• Pediatric patients (children and older infants): give 15–30 mg/kg once daily (maximum 1 g per day). 2

Renal Impairment Adjustments

• Do not lower the mg/kg dose; instead extend the dosing interval to preserve concentration‑dependent bactericidal activity. 2
• Maintain a dose of 12–15 mg/kg but give it 2–3 times per week according to renal function. [1][2]
• Practical method: multiply serum creatinine (mg/dL) by 9 to obtain the dosing interval in hours. Example: creatinine = 2 mg/dL → dose every 18 h. 1
• For patients on hemodialysis, administer the dose after dialysis using 12–15 mg/kg 2–3 times weekly. 2

Obesity Adjustments

• Calculate dosing weight as ideal body weight (IBW) + 40 % of excess weight. 1
• IBW formulas:
  
  • Male = 50 kg + 2.3 × (height (cm) − 152.4)/2.54
  • Female = 45.5 kg + 2.3 × (height (cm) − 152.4)/2.54
  • (Both formulas from Thorax 2017) 1

Therapeutic Drug Monitoring (TDM)

• Target peak concentrations: 25–35 mg/L for daily dosing; 65–80 mg/L for thrice‑weekly dosing. 1
• Target trough concentration: < 5 mg/L to avoid toxicity. 1
• Sample timing:
  
  • Peak – draw 60–120 min after infusion ends. 1
  • Trough – draw immediately before the next dose. 1
• Monitoring frequency:
  
  • Peak level measured during the first week; repeat if clinical response is poor. 1
  • Trough levels weekly for the first 4 weeks, then every two weeks once stable. 1

Safety Monitoring

• Renal function: check twice weekly in month 1, weekly in month 2, then fortnightly thereafter. Increase frequency if renal impairment emerges. 1
• Ototoxicity definition: a loss of 20 dB at any single frequency or 10 dB at two adjacent frequencies. 1

Special Populations & Contraindications

• Pregnancy: amikacin is contraindicated because of fetal nephrotoxicity and risk of congenital hearing loss. 2
• Concurrent loop diuretics markedly increase ototoxicity risk. 2

Critical Pitfalls

• Never reduce the mg/kg dose in renal impairment; always extend the dosing interval instead. 2
• Avoid using fixed 500 mg doses regardless of patient weight, as this can cause under‑dosing and treatment failure. (derived from cited dosing principles)

All facts are derived from peer‑reviewed sources (Thorax 2017 1 and American Journal of Respiratory and Critical Care Medicine 2003 2).

Amikacin Dosing and Safety Guidelines

Introduction to Amikacin Therapy

• The Centers for Disease Control and Prevention recommends a dose reduction to 10 mg/kg/day for patients over 59 years of age due to increased risk of ototoxicity and nephrotoxicity 3, 4, 5
• For children and older infants, the recommended dose is 15-30 mg/kg/day as a single daily dose 3, 4, 5
• In patients with renal insufficiency, the dose should be maintained at 12-15 mg/kg but the frequency reduced to 2-3 times per week 3, 4, 5

Dosing Adjustments and Monitoring

• The American Medical Association recommends administering the dose after dialysis to facilitate directly observed therapy and avoid premature drug removal 3, 4
• Target peak levels are 25-35 mg/L for daily dosing or 65-80 mg/L for three-times-weekly dosing; target trough levels should be <5 mg/L to prevent toxicity 6, 7
• Baseline assessment should include audiogram, vestibular testing, Romberg testing, and serum creatinine 3, 4, 5
• Monthly monitoring should include renal function assessment and questioning about auditory/vestibular symptoms 3, 4, 5

Safety Considerations

• Amikacin is absolutely contraindicated in pregnancy due to risk of fetal nephrotoxicity and congenital hearing loss 3, 4
• Nephrotoxicity occurs in 8.7% of patients overall, but only 3.4% in those without risk factors 3, 4
• Ototoxicity, including high-frequency hearing loss, occurs in 1.5-24% of patients, with higher rates in longer treatment courses and higher doses 3, 4
• Repeat audiogram and vestibular testing if any symptoms of eighth nerve toxicity develop 3, 4, 5

Special Clinical Contexts

• For CNS infections, amikacin has poor CSF penetration even with meningitis, which may necessitate higher systemic doses 3, 4, 8
• For obese patients, the dose should be adjusted using ideal body weight plus 40% of excess weight 6

Common Pitfalls to Avoid

• Do not reduce the milligram dose in renal impairment; instead extend the dosing interval 3, 4
• Do not use fixed 500 mg doses regardless of weight—this risks underdosing and treatment failure 7
• Do not continue therapy beyond 10 days without reassessing drug levels and monitoring for toxicity 3, 4

Amikacin Dosing for Complicated Intra‑Abdominal Infections

Dosage Recommendations

• For adults with complicated intra‑abdominal infections, administer amikacin 15–20 mg/kg once daily (every 24 h) and use serum drug‑concentration monitoring to individualize therapy. 9

Dosing Considerations

• Calculate the amikacin dose based on lean body mass and the estimated extracellular fluid volume rather than total body weight to improve pharmacokinetic targeting in this patient group. 9